UNICA IRIS Institutional Research Information System

SERPE, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 101.780
NA - Nord America 6.726
AS - Asia 2.545
SA - Sud America 405
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 6
AN - Antartide 1
Totale 111.535
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 100.034
US - Stati Uniti d'America 6.631
CN - Cina 1.005
SG - Singapore 909
UA - Ucraina 497
SE - Svezia 375
BR - Brasile 313
DE - Germania 256
VN - Vietnam 224
FI - Finlandia 176
GB - Regno Unito 174
FR - Francia 130
HK - Hong Kong 77
KR - Corea 64
IN - India 55
CA - Canada 54
AR - Argentina 38
BD - Bangladesh 34
TR - Turchia 25
PK - Pakistan 23
RU - Federazione Russa 22
ZA - Sudafrica 21
IQ - Iraq 19
BE - Belgio 18
IR - Iran 16
MX - Messico 16
PL - Polonia 16
ES - Italia 15
ID - Indonesia 15
EC - Ecuador 14
JP - Giappone 14
PH - Filippine 14
KE - Kenya 12
NL - Olanda 11
CO - Colombia 10
MA - Marocco 10
IE - Irlanda 9
AT - Austria 8
SA - Arabia Saudita 8
CH - Svizzera 7
EG - Egitto 7
EU - Europa 7
RS - Serbia 7
VE - Venezuela 7
AU - Australia 6
BG - Bulgaria 6
JM - Giamaica 6
JO - Giordania 6
TN - Tunisia 6
BO - Bolivia 5
CL - Cile 5
CR - Costa Rica 5
PE - Perù 5
UY - Uruguay 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
LT - Lituania 4
RO - Romania 4
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
MY - Malesia 3
NI - Nicaragua 3
PY - Paraguay 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
DZ - Algeria 2
GT - Guatemala 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
PR - Porto Rico 2
TW - Taiwan 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BW - Botswana 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GQ - Guinea Equatoriale 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 111.534
Salva come PNG Salva come JPEG
Città #
Cagliari 98.363
Uta 1.364
Woodbridge 599
Fairfield 577
Ashburn 486
Singapore 449
Dallas 402
Houston 402
Chandler 390
San Jose 322
Ann Arbor 316
Jacksonville 285
Boardman 274
Nyköping 268
Wilmington 251
Seattle 237
Beijing 227
Dearborn 171
Cambridge 170
Los Angeles 98
Helsinki 96
Nanjing 86
Ho Chi Minh City 80
Boston 79
New York 77
Lauterbourg 73
Santa Clara 71
Hefei 69
Hong Kong 68
Seoul 57
Shanghai 57
The Dalles 49
Hanoi 45
San Diego 45
Buffalo 35
Nanchang 35
Milan 34
Munich 32
Redwood City 32
Council Bluffs 30
Guangzhou 29
Changsha 28
Toronto 25
Tianjin 24
São Paulo 23
Hebei 22
Shenyang 22
Jinan 20
London 20
Verona 19
Atlanta 18
Brussels 16
Redondo Beach 16
Norwalk 15
Mountain View 14
Orange 14
Orem 14
Warsaw 14
Zhengzhou 14
Auburn Hills 13
Frankfurt am Main 13
San Francisco 13
Tokyo 13
Baghdad 12
Brooklyn 12
Chennai 12
Chicago 11
Nairobi 11
Jiaxing 10
Phoenix 10
Rome 10
Sassari 10
Waltham 10
Wuhan 9
Augusta 8
Da Nang 8
Denver 8
Dong Ket 8
Dublin 8
Hangzhou 8
Johannesburg 8
Montreal 8
Rio de Janeiro 8
Shenzhen 8
Thái Nguyên 8
Campinas 7
Columbus 7
Haiphong 7
Manchester 7
Nuremberg 7
Nürnberg 7
Pune 7
San Mateo 7
Stockholm 7
Amsterdam 6
Ankara 6
Bielefeld 6
Charlotte 6
Curitiba 6
Dhaka 6
Totale 107.524
Salva come PNG Salva come JPEG
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.979
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.731
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.434
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.340
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 3.300
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 3.158
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.767
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.702
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.698
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.546
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.434
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.368
null 2.211
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.200
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.190
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 2.085
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 2.084
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 2.077
null 1.987
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.883
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.781
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.730
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.719
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.714
null 1.699
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.689
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.671
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.669
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.589
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.523
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.511
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.484
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.472
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.371
null 1.362
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.328
null 1.063
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 842
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 809
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 800
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 791
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 787
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 781
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 781
null 768
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 741
Current medications for cancer cachexia 740
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 739
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 739
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 725
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 723
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 717
null 709
null 694
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 684
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 681
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 666
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 658
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 584
null 572
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 563
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 559
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 551
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 534
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 522
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 522
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 519
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 500
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 496
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 493
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 491
null 465
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 459
An innovative approach to CACS 454
null 450
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 417
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 416
null 413
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 412
null 390
null 342
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 331
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 330
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 319
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 313
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 308
null 304
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 270
null 267
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 248
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 210
Prognostic role of lipid profile in patients with advanced cancer 209
null 208
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 205
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 155
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 154
null 147
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 146
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 144
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 137
Totale 111.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.970
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.970
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021541 0 0 0 0 0 0 0 0 0 0 0 541
2021/20224.262 401 314 179 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20246.816 445 336 335 511 693 1.312 839 473 311 467 584 510
2024/20258.457 1.040 1.647 1.329 1.267 700 1.116 564 104 185 126 184 195
2025/20264.805 300 238 677 435 347 310 717 219 358 640 266 298
Totale 111.733